ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate
October 29, 2020CStone Pharmaceuticals announced today a licensing agreement with LegoChem Biosciences, Inc., for the development and commercialization of LCB71, a potential first-in-class/best-in-class antibody drug conjugate ("ADC"). -
LegoChem Biosciences, Iksuda collaborate to develop antibody-drug conjugates
April 22, 2020LegoChem Biosciences, based in Daejeon, South Korea, announced that it has entered a research collaboration and license agreement with Iksuda Therapeutics for the development of antibody-drug conjugates in oncology. -
LegoChem Biosciences, Takeda collaborate for immuno-oncology research
March 25, 2019Takeda gains certain rights to LCB’s antibody-drug conjugate (ADC) technology
Pharma Sources Insight January 2025
